NCCN Guidelines for Patients® | Esophageal Cancer - page 61

NCCN Guidelines for Patients
: Esophageal Cancer
Version 1.2013
Part 6: Adenocarcinomas
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
The long tube-
like digestive organ
A feeding tube
Lymph node:
A small
group of disease-fighting
nutritional intake:
Ingested food and drinks
The second
layer of the esophageal
Supportive care:
Treatment for symptoms of
a disease
surgical margins:
normal-looking tissue
around the edge of a tumor
Read pages 16–17
for definitions of
TNM scores.
Other regimens
• Paclitaxel and cisplatin
• Docetaxel and cisplatin
• Irinotecan and cisplatin
• Paclitaxel and fluoropyrimidine (5-FU or capecitabine)
• Docetaxel and fluoropyrimidine (5-FU or capecitabine)
Next steps:
When you are finished with cancer treatment, read Part 6.3 for
follow-up testing.
6.2 Locally advanced adenocarcinoma
These cancers have spread beyond the submucosa but not to distant sites. They
include T2, T3, and T4 tumors without cancer in the nearby lymph nodes. Also
included are T1b, T2, T3, or T4 tumors with cancer in the nearby lymph nodes.
On the following pages, cancer in nearby lymph nodes is represented by ‘N+’
since the number of lymph nodes with cancer can’t be known before surgery.
Surgery may be a treatment option for these cancers. Your doctors will assess
if you are able to undergo surgery by testing your lungs, heart, and nutritional
intake. Your doctors will also assess if chemotherapy and chemoradiation would
do more to help than harm. Surgical and nonsurgical options are presented on the
next few pages.
endoscopic mucosal
1...,51,52,53,54,55,56,57,58,59,60 62,63,64,65,66,67,68,69,70,71,...100
Powered by FlippingBook